Arcutis Biotherapeutics (NASDAQ:ARQT) versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head to Head Survey

Arcutis Biotherapeutics (NASDAQ:ARQT) and Oncotelic Therapeutics (OTCMKTS:OTLC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Arcutis Biotherapeutics and Oncotelic Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1	1	6	1	2.78
Oncotelic Therapeutics	0	0	0	0	0.00

Arcutis Biotherapeutics presently has a consensus target price of $29.00, indicating a potential upside of 1.65%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Arcutis Biotherapeutics is more favorable than Oncotelic Therapeutics.

Valuation and Earnings

This table compares Arcutis Biotherapeutics and Oncotelic Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$196.54 million	17.78	-$140.04 million	($0.36)	-79.25
Oncotelic Therapeutics	$70,000.00	564.59	-$4.52 million	N/A	N/A

Oncotelic Therapeutics has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Volatility & Risk

Arcutis Biotherapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500.

Profitability

This table compares Arcutis Biotherapeutics and Oncotelic Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-13.94%	-29.69%	-12.52%
Oncotelic Therapeutics	N/A	-22.16%	-6.17%

Summary

Arcutis Biotherapeutics beats Oncotelic Therapeutics on 6 of the 11 factors compared between the two stocks.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.